TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX - Free Report) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

TCRX has been the subject of a number of other reports. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of TScan Therapeutics in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $12.00.

TScan Therapeutics Stock Performance

TCRX stock traded down $0.43 during trading hours on Friday, hitting $4.39. 220,785 shares of the stock were exchanged, compared to its average volume of 246,690. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $232.56 million, a P/E ratio of -4.14 and a beta of 0.79. The company has a 50-day simple moving average of $5.33 and a two-hundred day simple moving average of $6.51.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. The business had revenue of $0.54 million during the quarter, compared to analysts' expectations of $1.55 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, analysts forecast that TScan Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Transactions at TScan Therapeutics

In related news, Director Barbara Klencke bought 5,000 shares of the firm's stock in a transaction on Monday, September 23rd. The shares were purchased at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the purchase, the director now owns 45,000 shares in the company, valued at $238,050. This represents a 12.50 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Zoran Zdraveski sold 164,686 shares of the firm's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders acquired 15,000 shares of company stock valued at $82,550. Corporate insiders own 2.76% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Stifel Financial Corp increased its position in TScan Therapeutics by 3.9% in the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company's stock valued at $494,000 after acquiring an additional 3,733 shares during the period. Dimensional Fund Advisors LP acquired a new stake in TScan Therapeutics in the second quarter valued at $70,000. MetLife Investment Management LLC raised its position in TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company's stock worth $116,000 after purchasing an additional 13,164 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics during the 2nd quarter worth about $90,000. Finally, SG Americas Securities LLC bought a new stake in shares of TScan Therapeutics in the 3rd quarter valued at about $78,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.